ArticleThe Journal of clinical investigation2022
Predicting cognitive decline in Parkinson's disease using FDG-PET-based supervised learning.
Article in The Journal of clinical investigation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 3 syntheses or guidelines pooled it, 37 citations in OpenAlex.
- The Role of Machine Learning in Cognitive Impairment in Parkinson Disease: Systematic Review and Meta-Analysis.Journal of medical Internet research · 2025Pooled it
- Houston, We Have AI Problem! Quality Issues with Neuroimaging-Based Artificial Intelligence in Parkinson's Disease: A Systematic Review.Movement disorders : official journal of the Movement Disorder Society · 2024Pooled it
- Machine learning for the detection and diagnosis of cognitive impairment in Parkinson's Disease: A systematic review.PloS one · 2024Pooled it
- A review of FDG-PET biomarker analysis methods in Parkinson's disease.Journal of Parkinson's disease · 2026Review
- Identifing two distinct cortical progression subtypes of Parkinson's disease through multimodal neuroimaging.European journal of nuclear medicine and molecular imaging · 2026Article
- Motor-Derived Digital Biomarkers for Identifying Low-MoCA Status in People with Parkinson's Disease.Sensors (Basel, Switzerland) · 2026Article
- Assessment of mental and behavioural non-motor symptoms of Parkinson's Disease using Artificial Intelligence (AI): a systematic review.Communications medicine · 2026Article
- The phase average wavelength of alpha rhythm in EEG signals of patients with Parkinson's disease combined with cognitive impairment.PloS one · 2026Article
- Impact of Additional Occipital Involvement in Parkinson's Disease With Posterior Cortical Hypoperfusion.Journal of movement disorders · 2026Article
- Subitem-level multi-scale assessment and machine learning for three-class cognitive status classification in Parkinson's disease.NPJ Parkinson's disease · 2025Article
- Construction of a mild cognitive impairment prediction model for Parkinson's disease patients on the basis of multimodal data.NPJ Parkinson's disease · 2025Article
- Improving the Quality of Brain PET Images Using MR-Guided PET Reconstruction Technique With Integrated PET/MR.Human brain mapping · 2025Article
- Cognitive disorders and parkinson's disease: a literature review.Journal of neural transmission (Vienna, Austria : 1996) · 2025Review
- The combination of theScientific reports · 2025Article
- Correlation of Parkinson's disease severity andQuantitative imaging in medicine and surgery · 2025Article
- Understanding glucose metabolism and insulin action at the blood-brain barrier: Implications for brain health and neurodegenerative diseases.Acta physiologica (Oxford, England) · 2025Review
- Modeling and validation of wearable sensor-based gait parameters in Parkinson's disease patients with cognitive impairment.Frontiers in aging neuroscience · 2025Article
- Characteristics of cerebral glucose metabolism in patients with cognitive impairment in multiple system atrophy.Frontiers in aging neuroscience · 2025Article
- Should Artificial Intelligence Play a Durable Role in Biomedical Research and Practice?International journal of molecular sciences · 2024Review
- Prediction of cognitive decline in Parkinson's disease based on MRI radiomics and clinical features: A multicenter study.CNS neuroscience & therapeutics · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BackgroundCognitive impairment is a common symptom of Parkinson's disease (PD) that increases in risk and severity as the disease progresses. An accurate prediction of the risk of progression from the mild cognitive impairment (MCI) stage to the dementia (PDD) stage is an unmet clinical need.MethodsWe investigated the use of a supervised learning algorithm called the support vector machine (SVM) to retrospectively stratify patients on the basis of brain fluorodeoxyglucose-PET (FDG-PET) scans. Of 43 patients with PD-MCI according to the baseline scan, 23 progressed to PDD within a 5-year period, whereas 20 maintained stable MCI. The baseline scans were used to train a model, which separated patients identified as PDD converters versus those with stable MCI with 95% sensitivity and 91% specificity.ResultsIn an independent validation data set of 19 patients, the AUC was 0.73, with 67% sensitivity and 80% specificity. The SVM model was topographically characterized by hypometabolism in the temporal and parietal lobes and hypermetabolism in the anterior cingulum and putamen and the insular, mesiotemporal, and postcentral gyri. The performance of the SVM model was further tested on 2 additional data sets, which confirmed that the model was also sensitive to later-stage PDD (17 of 19 patients; 89% sensitivity) and dementia with Lewy bodies (DLB) (16 of 17 patients; 94% sensitivity), but not to normal cognition PD (2 of 17 patients). Finally, anti-PD medication status did not change the SVM classification of the other set of 10 patients with PD who were scanned twice, ON and OFF medication.ConclusionsThese results potentially indicate that the proposed FDG-PET-based SVM classifier has utility for providing an accurate prognosis of dementia development in patients with PD-MCI.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.